Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5902915 | 0.89 | GSR (0.52) | GSRTRPA1LMNAF9F10 | |
| SCHEMBL16398170 | 0.87 | GSR (0.50) | GSRTRPA1LMNATAAR1KDM4E | |
| SCHEMBL14935978 | 0.87 | GSR (0.50) | GSRTRPA1LMNATAAR1KDM4E | |
| SCHEMBL14935912 | 0.87 | GSR (0.50) | GSRTRPA1LMNATAAR1KDM4E | |
| SCHEMBL8602813 | 0.85 | GSR (0.49) | GSRTRPA1LMNATAAR1KDM4E | |
| SCHEMBL1262426 | 0.83 | GSR (0.55) | GSRTRPA1LMNAF9F10 | |
| SCHEMBL13843585 | 0.82 | TRPA1 (0.47) | GSRTRPA1LMNATAAR1KDM4E | |
| SCHEMBL14945485 | 0.82 | TRPA1 (0.47) | GSRTRPA1LMNATAAR1KDM4E | |
| SCHEMBL2482267 | 0.81 | GSR (0.53) | GSRTRPA1LMNAKDM4ESLC6A4 | |
| SCHEMBL18982890 | 0.81 | TRPA1 (0.47) | GSRTRPA1LMNAHTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642588-A2 | Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease | Chemokine Therapeutics Corporation (CA) | 2006-04-05 | — | — | EP | claimed |
| CN-113769114-A | Cancer models and related methods | 恩格姆生物制药公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-109311959-A | peptide analogs | 艾得佩索拉公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-108997490-A | Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use | 克里斯托弗·J·索尔斯 | 2018-12-14 | — | — | CN | disclosed |
| CN-108697776-A | Interleukin-10 in the production of antigen-specific CD8+ T cells and methods of use thereof | 阿尔莫生物科技股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-104271596-B | Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use | 克里斯托弗·J·索尔斯 | 2018-09-18 | — | — | CN | disclosed |
| CN-108472324-A | Interleukin-15 composition and application thereof | 阿尔莫生物科技股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| CN-107921085-A | Methods and compositions for treating aging-related disorders | 小利兰·斯坦福大学托管委员会 | 2018-04-17 | — | — | CN | disclosed |
| CN-106573072-A | Methods of lowering serum cholesterol | 阿尔莫生物科技股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106573073-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2017-04-19 | — | — | CN | disclosed |
| US-6355457-B1 | NUCLEOTIDE SEQUENCE OF HYBRIDIZED COMPLEMENT; GENETIC ENGINEERING, GENE EXPRESSION; ANTICARCINOGENIC AGENTS; SORANGIUM ISOLATES | NOVARTIS AG (CH) | 2002-03-12 | — | — | US | disclosed |
| US-6355459-B1 | NUCLEOTIDE SEQUENCE OF HYBRIDIZED COMPLEMENT; GENETIC ENGINEERING, GENE EXPRESSION; ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-03-12 | — | — | US | disclosed |
| US-6346404-B1 | NUCLEOTIDE SEQUENCE OF POLYKETIDE SYNTHASE; FOR RECOMBINANT PRODUCTION OF ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-02-12 | — | — | US | disclosed |
| CN-1291239-A | Fermentation preparation method of cell inhibitor and crystal form thereof | NOVARTIS AG (CH) | 2001-04-11 | — | — | CN | disclosed |
| EP-1088078-A2 | GENES FOR THE BIOSYNTHESIS OF EPOTHILONES | Novartis AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| US-6194181-B1 | PRODUCING EPOTHIOLONES IN A CULTURE MEDIUM BY PROVIDING MICROORGANISMS SUCH AS MYXOBACTERIA WHICH PRODUCE EPOTHIOLONES, AND ADDING A COMPLEX-FORMING AGENT SOLUBLE IN THE CULTURE MEDIUM, SUCH AS CYCLODEXTRINS; ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-02-27 | — | — | US | disclosed |
| EP-1054994-A2 | FERMENTATIVE PREPARATION PROCESS FOR CYTOSTATICS AND CRYSTAL FORMS THEREOF | Novartis AG (CH) | 2000-11-29 | — | — | EP | disclosed |
| US-6121029-A | NUCLEOTIDE SEQUENCES ENCODING AT LEAST ONE POLYPEPTIDE FROM POLYKETIDE SYNTHASE; FOR RECOMBINANT PRODUCTION OF ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2000-09-19 | — | — | US | disclosed |
| WO-1999066028-A2 | GENES FOR THE BIOSYNTHESIS OF EPOTHILONES | NOVARTIS AG (CH) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999042602-A2 | FERMENTATIVE PREPARATION PROCESS FOR CYTOSTATICS AND CRYSTAL FORMS THEREOF | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |